Active Ingredient(s): Neratinib Maleate
FDA Approved: * July 17, 2017
Pharm Company: * PUMA BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nerlynx Overview

Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.[2][3] The most common side effect is diarrhea, which affects nearly all patients.[3] Other common side effects include nausea (feeling sick), vomiting, tiredness, belly pain, rash, decreased appetite, stomatitis (sore, inflamed mouth), and muscle spasms.[3] Contents 1 Medical uses 2 ...

Read more Nerlynx Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nerlynx Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Neratinib Maleate
  • Tablet: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nerlynx: (1 result)

Sorted by National Drug Code
  • 70437-240 Nerlynx 48.31 mg Oral Tablet by Puma Biotechnology, Inc.

Other drugs which contain Neratinib Maleate or a similar ingredient: (1 result)